Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2016
|
| gptkbp:ATCCode |
A10BJ03
|
| gptkbp:brand |
Lyxumia
|
| gptkbp:CASNumber |
320367-13-3
|
| gptkbp:chemicalFormula |
C215H347N61O65S
|
| gptkbp:contraindication |
hypersensitivity to lixisenatide
|
| gptkbp:drugClass |
GLP-1 receptor agonist
|
| gptkbp:genericName |
gptkb:lixisenatide
|
| gptkbp:halfLife |
2-4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adlyxin
|
| gptkbp:indication |
gptkb:type_2_diabetes
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:marketedIn |
gptkb:European_Union
gptkb:United_States |
| gptkbp:mechanismOfAction |
slows gastric emptying
stimulates insulin secretion suppresses glucagon secretion |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea headache |
| gptkbp:bfsParent |
gptkb:GLP-1_agonists
|
| gptkbp:bfsLayer |
7
|